Founded in 2015, VitaDX develops and markets cancer diagnostic solutions that combine image analysis and artificial intelligence applied to cytology with its patented VisioCyt® technology. Its mission is to develop innovative and effective solutions that have a significant impact on healthcare systems for the benefit of the greatest number of patients. After several years of development and a prospective multicenter clinical study, its first solution, VisioCyt® Bladder, CE IVDR marked, allows for the diagnosis and monitoring of bladder cancer using a simple urine sample. Other devices are under development, including for bladder cancer screening and thyroid cancer diagnosis.